维昇药业隆培生长激素获批：1年长高11厘米 百亿市场格局生变

Core Viewpoint - The approval of Weisheng Pharmaceutical's long-acting growth hormone injection, Longpei, marks a significant advancement in the treatment of pediatric growth hormone deficiency (PGHD) in China, offering a more convenient alternative to daily injections and potentially capturing a substantial share of the high-end market for growth hormone deficiency [1][2][12]. Company Summary - Weisheng Pharmaceutical's Longpei growth hormone injection is the first and only product in China to demonstrate superior efficacy over daily formulations in Phase III clinical trials [1][12]. - The product is based on TransCon technology, which allows for the slow release of a growth hormone structurally identical to the body's own, providing a theoretical safety advantage [6][20]. - The company plans to pursue both original imports and local production partnerships to enhance market access and distribution [9][20]. Industry Summary - The Chinese growth hormone market has grown from 4 billion yuan in 2018 to 11.6 billion yuan in 2023, with a compound annual growth rate (CAGR) of 23.9%, and is projected to reach 28.6 billion yuan by 2030 [4][14]. - The long-acting growth hormone segment is expected to surpass short-acting products within two years and capture 80% of the market by 2030, indicating a significant shift towards long-acting formulations [4][15]. - The market is currently dominated by Jinsai Pharmaceutical, which is expected to generate revenues of 10.671 billion yuan in 2024, with a net profit of 2.678 billion yuan [15]. Market Dynamics - The market is experiencing a transition from volume expansion to value competition, with a focus on innovative, high-end products [14][15]. - Despite the growth in diagnosis and treatment rates for growth hormone deficiency (GHD) in China, the overall penetration remains significantly lower than in developed countries due to factors such as daily injection compliance challenges, high treatment costs, and limited insurance coverage [2][14]. - Recent price adjustments in long-acting growth hormones are anticipated to improve drug accessibility and create a market split between "insurance-inclusive" and "high-quality" segments [19][20]. Competitive Landscape - The competitive landscape is intensifying with the entry of new players like Teva Biopharma, which is expected to challenge Jinsai Pharmaceutical's dominance in the long-acting segment [5][15]. - The market is characterized by a variety of technological approaches to long-acting growth hormones, including PEGylation and fatty acid side-chain modification, with Weisheng's TransCon technology offering a distinct alternative [20]. - The industry is also witnessing a shift in payment structures and competitive logic, with a growing emphasis on private hospitals and high-end medical institutions for distribution [9][20].